Empagliflozin: Cardio-Renal Benefits in HF, LVEF Above 40% Regardless of CKD Status
The EMPEROR-Preserved trial compared the efficacy and safety of empagliflozin with placebo in adults with heart failure and preserved ejection fraction, with and without diabetes.